RxDoctor Payments Data

Mounir Sanhaji, MD

Pain Management · Columbus, OHNPI 1417038324

Payments from drug & device makers

$2,073in general payments, 2019–2025

Across 82 payments — averaging $25.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$925
  • Collegium Pharmaceutical, Inc.$407
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$335
  • AbbVie$90
  • Pfizer$63
  • Abbott$54
  • plus $200 from 10 others

What the payments were for

  • Travel & lodging$87242%
  • Food & beverage$1,17857%
  • Education$241%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few pain management providers in Ohioto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$99,582
Medicare patients
77
Services billed
3,384

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate68$58,452
BelbucaBuprenorphine Hcl35$27,692
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen751$23,161
OxycontinOxycodone Hcl22$14,377
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen320$7,926
Gabapentin484$7,703
LinzessLinaclotide11$5,853
Oxycodone Hcl206$3,205
Fentanyl36$3,176
Morphine Sulfate ErMorphine Sulfate140$2,842
Naloxone Hcl45$2,815
Buprenorphine13$2,554
Methadone Hcl155$2,516
Tizanidine Hcl230$1,757
Pregabalin108$1,746

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$407$86,144103 claims
AbbVieLinzess$90$5,85311 claims
Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate$21$3,24730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few pain management providers in Ohioon file to place this against a meaningful peer group, so we don't.

Other pain management in Columbus

Where these figures come from

Is this you, or does something look wrong? →